背景和目的：評估Isoflavone 在治療男性更年期的攝護腺肥大的效果。方法：25位有男性更年期症狀或男性更年期肥大症狀的病人給予兩個月，每天13 克的Phytogen(r)。以量表定期追蹤各種症狀改良的結果，並測定血清中總睪固酮濃度、PSA、攝護線的大小以作為藥效的評估。結果：對於原本血清總睪固酮低下的病人，補充Isoflavone 一個月和兩個月後，可以發現改善血清濃度回到正常；最大尿流速的平均值也在兩個月後發現改善(從每秒.17 豪升回升到12 豪升)，某位病人的症狀，如疲勞、全身無力、皮膚萎縮也得到改善，所有的病人都沒出現明顯的副作用；攝護腺的大小與PSA 值也未改變。結論：服用Isoflavone 二個月後治療男性更年期的攝護腺肥大的症狀，在本研究中雖無法呈現對所有的病人或整體性的病狀有療效，但在某些病人的某些症狀的改善上確有功效，而且沒有副作用出現，可以作為男性更年期的另類療法。

Background and purpose: To elucidate the effect of isoflavone on male climacterics andprostatism. Methods: We conducted an open-labeled clinical study of isoflavone on 25 maleswith climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen®) was givendaily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months. Periodic examinationsweremade of the prostate size, PSA (prostate specific antigen), and uroflow, as well as a follow-upquestionnaires with subjective screening of the voiding function, sexual function, and maleclimacteric symptoms were given. Results: Neither the prostate size nor serum PSA level of anypatient were altered. For patients with hypogonadism at the baseline (with an average serumtestosterone level of 0.74 ng/ml, n = 8), isoflavone was shown to have resolved the testosteronedeficiency after 1 month (average testosterone level of 3.04 ng/ml) and 2 months (averagetestosterone level of 3.37 ng/ml) of treatment. The peak flow rate of the urine was also notablyimproved after 2 months of isoflavone treatment (with an increase in the average peak flow rate offrom 6.17 to 12ml/s). Some of themale climacteric symptoms such as fatigue, generalweakness, andskin atrophy were found to have diminished by scoring in the group of diseased patients. As anatural product, isoflavone was quite acceptable to these middle-aged to elderly patients, and noadverse effects were recorded. Conclusion: Although neither all of the patients nor all of thesymptoms were responsive to 2 months of treatment with this medication in our series, isoflavonedid, however, truly benefit some patients with climacteric symptoms and/or prostatism and maybe an alternative therapy for aging males.